Cited 40 times in
Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.